-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 BlWMo0Ehb/3dWuvlfSejjaMuJaEIAW6vlBy7Hd54AAYi+gGST/BknjI1EZBxo85P
 UpiJlRj/hehH3j/5NjDZBw==

<SEC-DOCUMENT>0000950103-04-001806.txt : 20041227
<SEC-HEADER>0000950103-04-001806.hdr.sgml : 20041224
<ACCEPTANCE-DATETIME>20041227151203
ACCESSION NUMBER:		0000950103-04-001806
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20041224
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041227
DATE AS OF CHANGE:		20041227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SHIRE PHARMACEUTICALS GROUP PLC
		CENTRAL INDEX KEY:			0000936402
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29630
		FILM NUMBER:		041226328

	BUSINESS ADDRESS:	
		STREET 1:		HAMPSHIRE INTL BUSINESS PARK
		STREET 2:		CHINEHAM BASINGSTOKE
		CITY:			HAMPSHIRE ENGLAND RG
		STATE:			X0
		BUSINESS PHONE:		1264333455

	MAIL ADDRESS:	
		STREET 1:		HAMPSHIRE INTL BUSINESS PARK
		STREET 2:		CHINEHAM BASINGSTOKE
		CITY:			HAMPSHIRE ENGLAND RG
		STATE:			X0
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dec2704_8k.htm
<TEXT>
<HTML>
<HEAD>
   <TITLE>8-K</TITLE>
</HEAD>


<body leftmargin="50p" marginwidth="50p">
<div align=center>
<TABLE WIDTH="90%" border=0 cellpadding=0 cellspacing=0 BORDERCOLOR="#000000">
  <TR>
    <TD width=27%></TD>
    <TD width=58%> </TD>
    <TD width=15%> </TD>
  </TR>
  <TR valign="bottom">
    <TD align=left nowrap>&nbsp;</TD>
    <TD nowrap colspan=1 align=left>&nbsp; </TD>
    <TD nowrap colspan=1></TD>
  </TR>
  <TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD WIDTH="15%"></td>
  </TR>
  <TR valign="bottom">
    <TD colspan="3" align=center nowrap> <B><FONT size=2 face="serif">UNITED STATES</FONT></B>&nbsp; </TD>
    </TR>
  <TR valign="bottom">
    <TD colspan="3" align=center nowrap> <B><FONT size=2 face="serif">SECURITIES
      AND EXCHANGE COMMISSION</FONT></B>&nbsp; </TD>
    </TR>
  <TR valign="bottom">
    <TD colspan="3" align=center nowrap>&nbsp;</TD>
  </TR>
  <TR valign="bottom">
    <TD colspan="3" align=center nowrap> <B><FONT size=2 face="serif">Washington,
      D.C. 20549</FONT></B>&nbsp; </TD>
    </TR>
  <TR valign="bottom">
    <TD nowrap align=center>&nbsp;</TD>
    <TD nowrap colspan=1 align=center>&nbsp;</TD>
    <TD nowrap colspan=1></TD>
  </TR>
  <TR valign="bottom">
    <TD nowrap align=center>&nbsp;</TD>
    <TD nowrap colspan=1 align=center>&nbsp;</TD>
    <TD nowrap colspan=1></TD>
  </TR>
  <TR valign="bottom">
    <TD colspan="3" align=center nowrap><font size=2 face="serif">FORM 8-K</font></TD>
    </TR>
  <TR valign="bottom">
    <TD colspan="3" align=center nowrap>&nbsp;</TD>
  </TR>
  <TR valign="bottom">
    <TD colspan="3" align=center nowrap><font size="2" face="serif">CURRENT REPORT
    </font> </TD>
  </TR>
  <TR valign="bottom">
    <TD colspan="3" align=center nowrap>&nbsp;</TD>
  </TR>
  <TR valign="bottom">
    <TD colspan="3" align=center nowrap><font size="2" face="serif">Pursuant to Section 13 or 15(d) of the <br>
Securities Exchange Act of 1934</font></TD>
  </TR>
  <TR valign="bottom">
    <TD colspan="3" align=center nowrap>&nbsp;</TD>
  </TR>
</TABLE>
</div>
<BR>

<div align=center>
  <TABLE WIDTH="90%"  BORDER="0" CELLSPACING="0" CELLPADDING="0">
  <TR>
    <TD WIDTH="33%" align="right" valign="top" NOWRAP><FONT SIZE=2 FACE="serif">Date of Report (Date of earliest event reported):&nbsp;&nbsp; </FONT></TD>
    <td WIDTH="67%" STYLE="border-color: #000000;
Border-bottom-Width: 0.5pt; border-bottom-style: solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT size="2">December
        24,
      2004</FONT> </TD>
  </TR>
</TABLE>
<BR>
<TABLE WIDTH="90%"  BORDER="0" CELLSPACING="0" CELLPADDING="0">
  <TR>
    <TD ALIGN="CENTER" VALIGN="BOTTOM"><B><FONT face="serif">Shire Pharmaceuticals Group plc</FONT></B></TD>
  </TR>
  <TR>
    <TD ALIGN="CENTER" VALIGN="BOTTOM"><hr COLOR="#000000" NOSHADE SIZE="1"></TD>
  </TR>
  <TR>
    <TD ALIGN="CENTER"><FONT size=2 face="serif">(Exact name of registrant as specified in its
    charter)</FONT></TD>
  </TR>
  <TR>
    <TD ALIGN="CENTER">&nbsp;</TD>
  </TR>
  <TR>
    <TD ALIGN="CENTER"><font size="2" face="serif">England and Wales</font></TD>
  </TR>
  <TR>
    <TD ALIGN="CENTER"><hr color="#000000" noshade size="1"></TD>
  </TR>
  <TR>
    <TD ALIGN="CENTER"><font size=2 face="serif">(State or other jurisdiction of incorporation)</font></TD>
  </TR>
</TABLE>
<BR>
<TABLE WIDTH="70%"  BORDER="0" CELLSPACING="0" CELLPADDING="0">
  <TR VALIGN="BOTTOM">
    <TD width="40%" ALIGN="CENTER"><font size="2" face="serif">0-29630</font></TD>
    <TD ALIGN="CENTER"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="40%" ALIGN="CENTER"><font size="2" face="serif">98-0359573</font></TD>
  </TR>
  <TR VALIGN="TOP">
    <TD WIDTH="40%" ALIGN="CENTER"><font size=2 face="serif">(Commission File Number)</font></TD>
    <TD WIDTH="34%" ALIGN="CENTER">&nbsp;</TD>
    <TD WIDTH="40%" ALIGN="CENTER" nowrap><FONT SIZE=2 FACE="serif">(IRS Employer Identification
    No.) </FONT></TD>
  </TR>
</TABLE>
<BR>
<TABLE WIDTH="90%"  BORDER="0" CELLSPACING="0" CELLPADDING="0">
  <TR>
    <TD ALIGN="CENTER" VALIGN="BOTTOM"><FONT size="2" face="serif">Hampshire International Business Park, Chineham, Basingstoke,
        <br>
        Hampshire,

RG24 8EP England</FONT> </TD>
  </TR>
  <TR>
    <TD VALIGN="BOTTOM"><hr COLOR="#000000" NOSHADE SIZE="1"></TD>
  </TR>
  <TR>
    <TD ALIGN="CENTER"><FONT SIZE=2 FACE="serif">(Address of principal executive
    offices)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Zip code)</FONT></TD>
  </TR>
</TABLE>
<BR>
<TABLE WIDTH="90%"  BORDER="0" CELLSPACING="0" CELLPADDING="0">
  <TR>
    <TD align="center" valign="top" NOWRAP><FONT size=2 face="serif">Registrant&#146;s telephone number, including area
    code&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif"> 44 1256 894 000</FONT></TD>
    </TR>
</TABLE>
<BR>
<TABLE WIDTH="90%"  BORDER="0" CELLSPACING="0" CELLPADDING="0">
  <TR>
    <TD ALIGN="CENTER" VALIGN="BOTTOM">&nbsp;</TD>
  </TR>
  <TR>
    <TD ALIGN="CENTER" VALIGN="BOTTOM"><hr COLOR="#000000" NOSHADE SIZE="1"></TD>
  </TR>
  <TR>
    <TD ALIGN="CENTER"><FONT size=2 face="serif">(Former name or former address, if changed
    since last report) </FONT></TD>
  </TR>
  <TR>
    <TD ALIGN="CENTER">&nbsp;</TD>
  </TR>
  <TR>
    <TD ALIGN="left"><font size=2 face="serif">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):</font></TD>
  </TR>
  <TR>
    <TD ALIGN="left">&nbsp;</TD>
  </TR>
  <TR>
    <TD ALIGN="left">&nbsp;</TD>
  </TR>
  <TR>
    <TD ALIGN="left"><font size=2 face="serif"><font size=2 face="wingdings">o</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></TD>
  </TR>
  <TR>
    <TD ALIGN="left">&nbsp;</TD>
  </TR>
  <TR>
    <TD ALIGN="left"><font size=2 face="serif"><font size=2 face="wingdings">o</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></TD>
  </TR>
  <TR>
    <TD ALIGN="left">&nbsp;</TD>
  </TR>
  <TR>
    <TD ALIGN="left"><font size=2 face="serif"><font size=2 face="wingdings">o</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></TD>
  </TR>
  <TR>
    <TD ALIGN="left">&nbsp;</TD>
  </TR>
  <TR>
    <TD ALIGN="left"><font size=2 face="serif"><font size=2 face="wingdings">o</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></TD>
  </TR>
</TABLE>
</div>
<P>&nbsp;</P>
<hr size=3 color=GRAY noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<br>
<br>

<P>
  <FONT size="2" face="Times New Roman, Times, serif">Item 8.01.&nbsp;&nbsp;Other
  Events  </FONT></P>
<P><FONT size="2" face="Times New Roman, Times, serif"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shire
    Pharmaceuticals Group plc has issued the press release attached as Exhibit
  99.01 which is incorporated by reference herein. </FONT></P>
<P><FONT size="2" face="Times New Roman, Times, serif">Item 9.01.&nbsp;&nbsp;Financial Statements and
Exhibits </FONT></P>
<P><FONT size="2" face="Times New Roman, Times, serif">  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)
Exhibits. The following exhibit is filed herewith: </FONT></P>
<P><FONT size="2" face="Times New Roman, Times, serif">99.01&nbsp;&nbsp;&nbsp;&nbsp; Press
Release dated December 24, 2004</FONT></P>
<P></P>
<br>
<br>
<hr size=3 color=GRAY noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<br>
<br>

<P align="center">
  <strong><FONT size="2" face="serif"><br>
  SIGNATURE </FONT>
  </strong></P>
<P align="left"> <font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="serif">Pursuant
  to the requirements of the Securities Exchange Act of 1934, the registrant has
  duly caused this report to be signed on its behalf by the undersigned hereunto
  duly authorized.</FONT></font></P>
<table width="90%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="50%">&nbsp; </td>
    <td colspan="2"><FONT size="2" face="serif"><strong>SHIRE PHARMACEUTICALS GROUP PLC </strong></FONT> </td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td width="5%">&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td valign="top"><font size="2">By:</font></td>
    <td valign="top"><p><FONT size="2" face="serif">/s/ A C Russell&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT></p></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td valign="top">&nbsp;</td>
    <td valign="top"><hr align="left" width="60%" size=1 noshade></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td valign="top">&nbsp;</td>
    <td valign="top"><font size="2" face="serif">Name:&nbsp;&nbsp;Angus Russell</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td valign="top">&nbsp;</td>
    <td valign="top"><font size="2" face="serif">Title:&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer </font></td>
  </tr>
  <tr>
    <td><FONT SIZE="2">Dated: December 24, 2004</FONT></td>
    <td valign="top">&nbsp;</td>
    <td valign="top">&nbsp;</td>
  </tr>
</table>
<P>&nbsp;</P>
<P align="center">
  <br>
</P>

<hr size=3 color=GRAY noshade>
<!-- *************************************************************************** -->
<!-- MARKER PAGE="sheet: 1; page: 1" -->
<br>
<br>

<P align="center">
  <strong><FONT size="2" face="serif">  EXHIBIT INDEX</FONT>
  </strong></P>

<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="7%" align="center"><font size="2" face="serif">Number</font></td>
    <td width="93%"><font size="2" face="serif">Description </font> </td>
  </tr>
</table>
<TABLE width="100%" border=0 cellspacing=0 cellpadding=0>
  <TR>
    <TD width="7%" align="center"><FONT size="2" face="serif">99.01</FONT></TD>
    <TD width="93%"> <font size="2">Press Release dated December 24, 2004</font></TD>
  </TR>
  <TR>
    <TD align="center">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
</TABLE>
<P><FONT size="2" face="serif"><br>
  </FONT></P>

<br>
<hr size=3 color=GRAY noshade>
<br>
</BODY>
</HTML>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.01
<SEQUENCE>2
<FILENAME>exhibit9901.htm
<TEXT>



<HTML>
<HEAD>
   <TITLE>exhibit9901</TITLE>
</HEAD>

<BODY bgcolor="#ffffff">

<table width="100%"  border="0" cellspacing="0" cellpadding="0">
     <tr>
          <td width="33%" valign="top"><b><font size=1 face="sans-serif">Shire Pharmaceuticals
          Group plc<br>
</font></b><font size=1 face="sans-serif">Hampshire International Business Park, <br>
Chineham, Basingstoke RG24 8EP UK <br>
Tel +44 1256 894000 Fax +44 1256 894708<br>
http://www.shire.com</font></td>
          <td>&nbsp;</td>
          <td align="right"><img src="ex9901x2x1.jpg"></td>
     </tr>
     <tr>
          <td width="33%">&nbsp;</td>
          <td>&nbsp;</td>
          <td>&nbsp;</td>
     </tr>
</table>

<P>
<B></B></P>
<P>&nbsp;</P>
<TABLE><TR>
  <TD nowrap>
<FONT size=2 face="sans-serif">24 December 2004</FONT></TD>
</TR></TABLE>
<br>
<TABLE><TR><TD nowrap>
<FONT size=2 face="sans-serif">Shire Pharmaceuticals Group plc (the "Company")</FONT></TD></TR></TABLE>
<P><FONT SIZE="2" face="Arial,Helvetica,sans-serif">The Company announces
    that it was notified on 24 December 2004 under Sections 198 to 202 of the
    Companies Act that on 23 December 2004 Franklin Resources, Inc. and its affiliates
    had holdings managed on behalf of investment clients of 62,872,992 ordinary
    shares of &pound;0.05p each in the capital of the Company. These holdings
represent 12.966 per cent of the issued ordinary share capital of the Company.</FONT></P>
<P>
<FONT size=2 face="sans-serif">T May </FONT><br>

<FONT size=2 face="sans-serif">Company Secretary</FONT></P>
<P>
<B><FONT size=2 face="sans-serif">For further information please contact:</FONT></B></P>
<P>
<B><FONT size=2 face="sans-serif">Investor Relations </FONT></B><FONT size=2 face="sans-serif"> </FONT></P>
<P>
<FONT size=2 face="sans-serif">Cl&eacute;a Rosenfeld               &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+44 1256 894 160 </FONT></P>
<br>
<P>
<B><FONT size=2 face="sans-serif">Notes to editors</FONT></B></P>
<P>
<B><FONT size=2 face="sans-serif">Shire Pharmaceuticals Group plc</FONT></B></P>
<P>
<FONT size=2 face="sans-serif">Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing
products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world&#146;s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug
delivery unit in the US. </FONT></P>
<P>
<FONT size=2 face="sans-serif">For further information on Shire, please visit the Company&#146;s website: </FONT><U><FONT color="#000065" size=2 face="sans-serif">www.shire.com</FONT></U><FONT size=2 face="sans-serif">.</FONT></P>

<HR noshade align="center" width="100%" size=2>

</BODY>

</HTML>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex9901x2x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex9901x2x1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``T)"@L*"`T+"@L.#@T/$R`5$Q(2
M$R<<'A<@+BDQ,"XI+2PS.DH^,S9&-RPM0%=!1DQ.4E-2,CY:85I08$I14D__
MVP!#`0X.#A,1$R85%29/-2TU3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/
M3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T__P``1"`"M`3,#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#TZBBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`J*59&9-C[5!^;'4U+10!1^U2\O@!.P
M(Z_CZU;\U`RJ6PS=!4<D(4,T2`N>Q/'UJN',,C`8=_XW8X`/I3W`OU#(C[MZ
MNX`ZJ.].@E\V,.!CMBI*0%'SI6DRK9)`95XZ=P:N*ZMPK`D>AJ*>',;^4H#M
MW'>H886$R%5*JIYR.?I[T]&!=HHHI`,B,A4^:`#GC![4^D(R",XSWIJ_NHOG
M<D*.6-`#Z*I&XDFDQ`0`HS\W&ZK,$HFC#@8S3L!)1112`****`"BBB@`HHHH
M`*J7UI+=>5Y5Y/;A'RWED?./0Y%6Z*``#``]****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`*B>!6??R#WP>OUJ6B@#.,C+C@HPR%1#T^H[U
M=CE!PC,OF8Y`-+)&&!9>'Q@-Z52*LK,\JE`,'([M[?6GHP-"F3>9Y3F$(9-I
MVAR<9[9Q4<-R)&`*%=PR,]ZGI;`5[$W7V.+[<(Q<;?W@C/RY]JL55U&T:]LI
M+=+B:W9Q_K(CAA3I+B"SCB6YN%7<1&ID8`NW^)H`L4CJ'4JPR#U%+31(C.R!
MU++C<`>1GUH`AN4A$6Z1"0O3;UIL3R1XWJB1'H,@;:M<&JMS$S2!]I8`8`'\
M)]:=P+*L&`(.0:6J<;FW^7;O+L3A>@]JM1N)$#*<@]*0#J***`"BBB@`HHHH
M`****`"BBB@`HK&M-?>[LEO(=&U(PR0^=&W[D^8.#@`29!P<\XZ>M/M]<^U0
M6DUOIE\XNHFE5?W0*`=FR_!/&/KSCG`!K45BIXB26TTVXBTV^==2.(0/*!'R
MEAG+\94$_AV/%)'XA:5(6CT746,SNB+N@R2O7_EI['\OI0!MT5D?V_$PM3#9
M7DHN)'CRH0>6R$APP9@>-K=,].,\4ZUUJ2XN_L[:1?P[6"N\AB*H2,C.V0G\
MA0!JT50N-6@M[P0/'*5W(CS`#9&[G"J><Y.1T!'(SC-%GJT%W=?9UCE0LK/"
MS@;9D4@%EP2<`D=<'D4`7Z*HKJL!U#[)LD&7,:RD`(\@&XH.<D@`GIC@\Y!J
M33[Z+4+<SPK*JAVC(E0HV5.#P>1TH`M4444`%%%%`!1110`4444`%,FC$J;3
MQ@Y!]#3Z*`((K?8_F/C?[=*GI'&Y2`2,]QVIH_=H`S9QQDT`/J"YM+>ZV?:8
M4E\MPZ;AG:PZ$5/10!A>)=:?388[>S4RZA<';#&$+?C7)6L\-A!#?P7LW]MF
MX"7,$C$M)EL%2N/Q'\Z](:-&=79067H2.16!KD5U+?PV^FZ?$)Y5)>_>-3Y*
M].#UW?Y^FL))*UA-'0#I2URVGZY#I4\FF:CJ27/D%4698G)7_KHW(!SQ74*0
MP!!!!&016;BT,K30,&+*0%W;V]<^U1F9TD_=X\K`95QU'>KQY%0I;HD@<9XS
M@9X%%P)LT54N+G#>7$?9F[+3X9&$ODNP;Y<AAW^M%@+%%%%(`HHHH`****`"
MBBB@#E/#T%[I&F6\9T34WN(K=8Y`]Y&Z$C'W`TI"\^@48^@%6;&/4-,OI'CT
MJ>:"\3SY%C>(&"4Y)C&7&1GTXR2<G<<=%10!Q>G:/>6%KX>D&FZB\]HW^DH;
MT.J8B9/E5I=HR6!&T=`>G0S"VOI+:RCN-%U,"&>:1Q!=11MABQ7#+*#_`!>O
M8^U==10!RVFV>HV2Z5&VG3&.*YE<[9(B84?<%#G<-S?-DD9[\D]=>P%P-6U!
MI;.6**1E,<K,A5\*!P`Q(Z=P*TJ*`,.]TI[S5\JMQ%;%XI9SO3RYF0AEP.6R
M"H!^Z,>M,T[39;6Y>^,%V4MXY([6U>2,L`S`D#&`!\HQN8GU(Z5OT4`8B6-U
M_:$<7E%;>*\>[\XL"'#*WR@9R"&;TQ@>_%G1$N(X;H7-K);EKJ5U#LAW*S$@
MC:3Z]ZTJ*`"BBB@`HHHH`****`"BBB@`HHHH`*;)&LB[7`(]Z=10`QI!&54@
MG<<#`I]%5[B.:5@BD+&>I[T`21S1R,51@2*>>E46CD15!14V'F0'M5Y6#*"#
MD'I3:`XF]\-&QM[LRSPPV9WLUTN[S=C')5EZ./UJS;>(+FVU!K1K>+[%`T4*
M*"?-V-PLGH5/'OS753PQW$+PS1K)&XVLK#((]#7,WVE)HC?VA:FXF#8@D:20
MM]FA/5E'4X.#WK2,N;21-K'4@TM<7X/DO9KA7BNGGMXB\5TSREUD;JCIGVX-
M==-=06[1K/,D9E;8@9L;F]!42CRNPTPEC/EL(E4,W6JP(@?9&J`K@-(PJ\"#
MR#4<D*LQ;!S['K]:28Q([A3`)7(45,#D9%9[9CVM+&"<?+&.BCUJU!-YH.0`
M1Z'(H:`FHHHI`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110!!+!YL@9VR@Z+[U72<QY9458VY`]:OU7>
M%45G122.=N>/RII@3@\4$`C!Z&J,3#SW99"0#N+$G&/2K<4T<OW&SCM2:`@O
M9/L-A+-;VK3-&NX0Q``M]*XF_M9UN4U#Q7$\T=R/*ABMGY@<\@!?7W'>O0:R
M=4TI+FY34"&FFM8V,$#'Y/,ZAL>O%7"7*Q-$'A)]1?2!_::R`JY6(RC#LG8L
M/6MVO.K"ZU9[FW>WOKB[O'D4S1[RJP#.&22,]!UPPKK+374O]8>SL86F@B!\
MZY!^16[*/4TYP=[@F:LL(D(;<RL.A%57(B+H/D4$$D'!:KPZ4UXTDQN4'!R*
MS3&16\V8U\Q@">F>"14]49(W,H\Q"W4,Q'&W_P"M4D-RFU5^8J/EWD<$TV@+
M5%%%(`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`(9XRP&S&1U4]&IEK"R`-)]X#`Y[59IDJL\95&VD]
MZ+@127:))L`+`?>(_AJ<$,`000:I%/(E6*!OF8?,",CZU+:F.-!$)0S#TIM`
M5]6TL:C;-`MQ);!R/,:(`,Z_W<UR!NKNRGNH+65[.UL7:-;:W`,A`&1(P(^<
M'OBO0*I7UA%<*9EAA^UHA$,SH"4;'!S]:J,K:,31#I.H&>QM/MSQ17LT0=H<
MX;_OD\UIBO.I[75;NYATXQS/?@!I;FY`(@^;(>.0<X/H:ZK3O$-G<W/V+,PD
M5C$LLB;5F=1\VT^O?%.4+:H29M.H92IZ'BJPM!D;FR%QC'&?K5JBL[E!13$4
M1@Y8D$D\GI3E8,`5.0>]`"T444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`R6,.C`<,1C-4S'Y85I
M/W:J<X!SN/M5^D*AL9`..13N!7A=V??(P0'[J9JS6>\+@R?+RQ.6;D8_I5A+
MA%"J3D``;^V:&@(M5T]-3TZ>T=VC\U0-Z]5(.0?S%<K=P7>CS?:+FWMKNZN9
MT%K!$"J^8!S(<]&([=Z[>JNH6%MJ-L;>[CWH2".<%2.A!'0U496]!-&-X=U^
MYU&]>SNTA\Q81*&B#+MYP593R&!KHZS8;;3]#M7F9Q&H`#S2MECSQECR>M:$
M;K(BO&P96&00<@CUI2LW=`AQ`(P>13&*PQ$JIP.RBGT5(P!R`:***`"BBB@`
MHHJGJ>HVVEV4EW>2!(D'XD]@/>@"YFC-><77Q%O;F80Z5IJ!G.$\PEV/_`1_
M]>J$OC3Q%;N?/N+97!P8?+!(^N.GXG-;>PF9^TB>K9%&:\BA\7ZA=77_`!--
M0O(H&/\`RY[$*_F.?SKM[329;BVCN]*\3:BZN,H\CK*A^JD4ITG#XAQGS;'3
M45FPWT\>D3W%W&AGMED\Q4.%8IGD>@./PS7'_P#"S5_Z!!_\"/\`[&IC3E+9
M#<DMST*BJVGW7VW3[:[V;//B63;G.,C.*LU!04451UG4/[+TJXOO*\WR%W;-
MV,\^M"5]$!>HKS[_`(6:O_0(/_@1_P#8UWZ'<@;U&:N4)0^)$QDI;#J***@H
M****`"BBB@`HHHH`****`"BBB@`HHHH`:Z!T*L,@U3E@\ME:5MT8P``.?QJ]
M2,H8$,,@]C0G8"M#-*92D@R<D'`^[5JJ5Q"(U`3<$8_.1R?:GV8<;N,(<8YS
MDTV!-/!%<0M#/&LD;C#(PR"/I574+R2Q6`064UP'D"$18^0>IJ]1BD`F:6J<
MZWYOX&@DA%H`?.5E)<^F#FK$LJ0IN<_3WHL!)12*=R@],C-%`"TE%8'B+Q$N
MFNEA8I]IU.?Y8H5_A)Z%O:FDY.R$W;<T=5U:RTFU-Q>S!%Z*HY9SZ`=ZX7Q+
M/)JZ0WNN;M.T],FWMAS/.?7;_#QW/2NGTCPZR7":GK<QOM3ZAC]R+V4=/QJM
MXW\,OK5LES9X%Y`"`#_RT7^[['TK6FXQDOS(E=HXC1+BVOM4ATP!-.LI20[(
MW[Q^"0&D/J<#`P/:NWD\`Z`\.$CG1L<.LQ)_7(KRNZM9[2=H;N&2&4=4D7!J
MW9:[JVGJ$L]0GC0=$W94?@>*Z9TV]8,R4DM)(NZAX3U>VOYX+>QN;B)'(258
M^''8UV/P[MM6L%N[/4+6:&#B2/S%Q\W0@?I6!IOQ"U6WE`OTBNXN_P`H1OS'
M'Z5Z%H>N66N6GGV;G*\/&WWD/N*RK2J<MI(N"C>Z9)JJ+'HE^%'6"4_B037A
M/;\*]XUC_D"WW_7O)_Z":\''056%V9-;='L%MX@TS1O#FE_;[@*[6L96-1N8
M_*.PJ.#Q]H$T@1I9XLG&Z2(X_3-<;I'@S4]<LDOY;B.)'4",RY8LH&!]!BL+
M5M,N-(U"2RNPOF)@Y4Y#`]"*2I4Y-J^HW.2UMH>Z12QS1+)"ZR1N,JRD$$>Q
MJCX@2SDT2Z34I'CM"G[QTZ@9[<&N8^%]_)-I]U8R'*V[JR9[!LY'YC]:WO&?
M_(IZC_US_J*P<>6?*:J5XW.(^Q>`N/\`B:WV?]T__$5Z@F-B[>F.*^?>XKZ!
MC_U:_05KB(\MM;D4G>YD:CXIT;3+Q[2]NS',@!9?+8XR,CD"I;+Q#I-]9S7<
M%XOD0G$DC@H`<9[XKS3X@?\`(WW?^['_`.@"LBP@U#4<:98H\NY_,\I>F<8W
M'Z>]-8>+BI7$ZKO8]6L_&6BWU_%96TTKRRMM0^40"?QKH*\WT+P5K&G:U97D
MYMS''(&<)(20/RK7^('B";3+6.PLG:.XN!N:13RB=./<G^1K.5-.2C!E*3M>
M1L:IXHT?2G\NZNU,O>.,;V'UQT_&L^/X@:"[A6>XC!_B:+C],UYYX<T.;7]2
M-NCA(T&^:0\[1G]2:Z;7_A_#9Z9+=:;<3220J6:.0`[P.N,`8-:.E3B^63U)
MYY/5'?V=[;7UN)[.=)HVZ,AS5BO$/#FMSZ)J:3QL3"Y`F3LR_P"(]:]MC=9$
M5T8,K`$$="*RJTW!EPGS(=1116184444`%%%%`!1110`4R5G5<QIO/IFGT4`
M(#Q2U&ZNS*5?:`>1CK3_`&H`6HGMTDDWN"W&,$\5+10``8``Z"BBB@#"\6:Z
MNA:29EVM<2'9"A/?U^@_PJIX.T$V=J-3U#,NI70WN[G<4!Z#)[^OY=JP/B;;
M71O[.[6%WMDCVE@,A6W9Y],C%=C8>)-&O;=)(M0ME+`$H\@5E]B#6S5J:MU,
M[WEJ:M<AK/CJ+2=5GL)-.E=H2!N$@&<@'T]ZZ9-0LI>(;J*4^D;!S^0KC/'W
MAJ>]==6T^-I)`@6:,#YB!T8#U[8I4E%RM(<V[>Z7]%\2Z=XIO'L;C34!$>\"
M;:X;!'`&/>K5_P""="O$(6U^S.>CP';C\.GZ5Y)#-/9W*RPR20S1GAE.&4UO
M?\)QXBV;/MJ_7R4S_*MY49)W@S)5$U[Q2\3:(V@ZJ;0S"9&021MT.TY'(]>#
M6K\-YI(_$_EJ3LEA8,/I@BN:FFN+ZZ,LSR3SR'DG+,QKT7X>^'+FP:74[^,Q
M22)Y<<3##`9R2?3.!5U7RT[2W)AK+0ZS6/\`D"WW_7O)_P"@FO!^WX5[QK/_
M`"!;[_KWD_\`037@^>/PJ,+LRJVZ/<_#P`\.::`,#[+'_P"@BO./B3_R-'_;
MNG\S7I'A[_D7=-_Z]8__`$$5YO\`$HC_`(2@?]>Z?S-9T/XC+J?`:GPI_P!;
MJ?TB_P#9JZKQG_R*>H_]<_ZBN5^%/^MU/Z1_^S5U/C/_`)%/4?\`KG_445/X
MP0^`\7[BOH&/_5K]!7S]W%?0,7^K7Z"KQ705'J>1?$#_`)&Z[_W8_P#T`5T'
MPKB0PZA+M&_<B[L<XP>*Y[X@$?\`"77?/\,?_H`KI/A6?]$U'_KHG\C53_@_
M<3'^(=Y7E/Q*5QXF4OG:UNA7Z9/]:]7KEO'/AY]9L%GM%W7EOG8N?OJ>J_7N
M/_KUST9*,[LUJ*\=#SOP_INK:G+.FD2F-XU!?$QCR#T^M;;>%/%Y4@W+D'@@
MWAY_6N=L;W4?#^IB:)7@G7Y6CE4C</0@]JW-1\?ZK>V;6Z106^\;6DCSNQ[9
M/%=<_:7]VUC"/+;4C_X0'7_^>5O_`-_A7IVB03VNC6=M=?ZZ*%$?!SR!CK7E
M7AO2-6UN]C42W26@.9)BS;<>@/<U["BA%"J,`#`%<]=O1-FM-+=(=1117.:A
M1110`4444`%%%%`!1110`4PQJ9!)CY@,9I]%`%6XG<$QPJQ8#D@=*9;OLE6-
M)/,5AD^JFKN*JR)([L$`B0<ENYIH"U12+RHYSQUHI`&W(P1FJG]EZ=OW_8+7
M=_>\E<_RJY10G8!`BA=J@`#H`*7%%%`&??:)I>H2>9>V$$K_`-]D&[\^M5?^
M$3T#_H%P?K_C6U15*4EU%9%"PT73-.8O8V,$+GC<J\_G5[%+12;;W'81E#*5
M8`@C!![U7_L^R_Y\[?\`[]+5FBB[`:JA%"JH"@8``X%1R6EM,^^6WBD;&,L@
M)J:BD!%#;00$F&&.//78H&?RISQK(A21%93U##(-/HH`K?V?9?\`/G;_`/?M
M:L`8I:*+W"Q!)9VTKEY;:%V/5F0$TZ*"*`$0Q)&#UV*!FI:*=V`48HHI`5KN
MPL[U-EY:PSJ.@D0-C\ZIQ^&]$B<.FE6@8<C]T#_.M6BFI-=160U4"@!0`!T`
M[4ZBBD,****`"BBB@`HHHH`****`"BBB@`HHHH`*;(F^-DSC(Q3J*`$0;45?
(08HI:*`/_]D_
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
